|Rapid Review complete
|Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension).
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
The HSE has approved reimbursement following confidential price negotiations, December 2022.